{"name":"Volition","slug":"volition","ticker":"VNRX","exchange":"NYSE American","domain":"volition.com","description":"VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.","hq":"Namur, Belgium","founded":0,"employees":"75","ceo":"Cameron Reynolds","sector":"Diagnostics / Oncology","stockPrice":2.22,"stockChange":-0.14,"stockChangePercent":-5.93,"marketCap":"$18M","metrics":{"revenue":1727384,"revenueGrowth":133.2,"grossMargin":100,"rdSpend":10081299,"netIncome":-23357027,"cash":1117028,"dividendYield":0,"peRatio":0.5,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Volition Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Volition reported its fourth quarter and full year 2023 financial results, with revenue of $1.4 million and a net loss of $23.3 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Volition Announces Collaboration with Merck KGaA to Develop Companion Diagnostic for Cancer Therapy","summary":"Volition announced a collaboration with Merck KGaA to develop a companion diagnostic for a cancer therapy.","drugName":"","sentiment":"positive"},{"date":"2023-08-17","type":"regulatory","headline":"Volition Receives CE Mark for Nu.Q Test for Early Detection of Cancer","summary":"Volition received CE mark for its Nu.Q test, a blood-based test for the early detection of cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPMnFfREo5cHE5RG5HTnZuenZPRlZoUGJLY1lzdGpzY1cyYXg3SVBaSkZkY0w0V3RFR2VzUlk1Z0ZfUk9uWmRUU1NpN2hZREFjWWVpYVEyX2U4eTdOanMwV1JBNGl1WDU4aFZuX1R2UzNTV1BJSnZlV0lrb1JMOGxNMGw1eUl0WjZUQldzVTJKSFB1TTZuU2E1aTFybXRqY2NDaHRNSEEyS3ZYYzNGQWFmaGtYc3Zhb29mWFA0?oc=5","date":"2026-03-31","type":"pipeline","source":"Stock Titan","summary":"Belgian agencies give VolitionRx €2M to advance tests for poorer countries - Stock Titan","headline":"Belgian agencies give VolitionRx €2M to advance tests for poorer countries","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTFBWTHZsZDRTaFJ6cjBSQWF1MnV3aHpqeFN0VU16SEQyRlUyYVp3ZlhPNFNkbjRCLWVfY0NhTXNTMDUtbHl4N25ZajM2Mmk4MGc0LWFvU0dvUVJNejZ2cHfSAWNBVV95cUxPVkZiLWdVMHBUMWpVa1d4T3hOdDVRbWVDVHJpZ2RRWjAyUEoxZjdnX2VPLUFNdDVjZHZLSVJ3dXVwdzhSdVdRVE1Td1RRazZ0cmZ1ZXY3a3o2MDhFVk1RYTFJdk0?oc=5","date":"2026-03-29","type":"earnings","source":"Bitget","summary":"Volition's Mayo Trauma Research May Influence Valuation During April Earnings Announcement - Bitget","headline":"Volition's Mayo Trauma Research May Influence Valuation During April Earnings Announcement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPZTluYlBTNjZwcVNxeHJianU5MXIzZ0N4YnhtNWIzTW50OG4wMnBWRXFuZW1QRFlPOTZyRndoWjNaWlVjcUJ5MjdsQTlxR21mQWlxQUk0U3RRR3VVc2RWMUlaX2s5UnlSaUtPM0Mtb3NvcnljVGdrVDRVdG8xa1k1TGZYMmw0UWMzM3B2MVRaSEx3cUN0c1hKZGhOb052VzhsbWw0VEF3RUdLTU15LXE3dmM1Z3BRU1lwM0RB?oc=5","date":"2026-03-26","type":"pipeline","source":"Stock Titan","summary":"A blood test before lung surgery helped flag higher-risk patients - Stock Titan","headline":"A blood test before lung surgery helped flag higher-risk patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNTXFvX0dqTEd5M1M0VzJLaVdhdXI3N3ZERTRyNWlzTFJaYWhmVTQ5dFBhRXluSDd5eV9IRVdzbk81Tm01MFIxcHpLNmJKQlFudUVZMEcxQ29yMU1HQVBFUkl3bHF0VFdvLVNPTkdUN3phWl9PNUNHTUM5S0ExMnVjYmQ4elNaeWlsck1NZ1FldjZTT1Q3VW5uMGlnUnBLRWZBMm50RXN4OWpTVHBwT3c?oc=5","date":"2026-03-25","type":"trial","source":"Stock Titan","summary":"Blood test detects 95% of stage I and II cancers in blinded study - Stock Titan","headline":"Blood test detects 95% of stage I and II cancers in blinded study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPZU5fMU1uQVdtdWxjNFJ3eVdPeklSUnA3U1cyWm43UlRuaFd5TDNfY0xzdnlwVndnZVJQZktmYjE1Z3UtU01KZEFvdkwwWDBiZFJKcGE3cTBkNGlTMHdTaEd0eTNGbzJ2dndMNEZWWE04Yy0xWkVYRDI4VnhtREdheDdsdGNTTW1HbnkyazFtRmRHV3NqekpvS2dLdS1DT2hMd1hqSTYzTXlpQk5DVEhrTmh5T1c2UTRsZkdJemx3?oc=5","date":"2026-03-18","type":"trial","source":"Stock Titan","summary":"New liquid biopsy from VolitionRx finds 49 of 49 cancers in early study - Stock Titan","headline":"New liquid biopsy from VolitionRx finds 49 of 49 cancers in early study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOZEh3TEVYNVIxT1FmVEVwWTk1VzF5ZmtNNEtkTWlnSjRKdUtTbVVXdDIxVEU0WEtZM2JTLWZEeXdwZmFPMmNhSGQ4MXA0VmctQkJUYU1lUlJ4cVdESmo0Tm9TYkkzMmViV1dFOEZ2MEFUZnNuYWtwbXBfOXpPTmFWajVDVTg4NzFIQVdxOERib0k3c3BHeGEzU01JYktVN0NVM1Z6c0hmbTNJdjkwdnBSb1B0T2o?oc=5","date":"2026-02-25","type":"pipeline","source":"Stock Titan","summary":"Simple blood test finds most cat lymphomas, unlocks $5M for VolitionRx - Stock Titan","headline":"Simple blood test finds most cat lymphomas, unlocks $5M for VolitionRx","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOWVVnTWJFVzZzVmJ4YnZja2dPbG1XMGhJakVFZjl4cnVBSFRGNV9xNngxN1BQNXZWUHE2LXQzTk96TU9aOVNYUnVEQzhScWEzeFZkQWpXMmtHOFFrNmZob0VfOW0yUTEzbnZnall6aHJFVW9PUnFBMFdvaWFYbUhwR0VYNGVJaVBHaVZvWUIxQ1lTTFlTLVBFcGR3STg2VmlrZE44dnUweHhUd3dTdE1LQkI1eHUzREVN?oc=5","date":"2026-02-10","type":"pipeline","source":"Stock Titan","summary":"VolitionRx nears 100 Nu.Q Discover clients, extends reach to Japan - Stock Titan","headline":"VolitionRx nears 100 Nu.Q Discover clients, extends reach to Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQVnZ3RlJCQTQ3TWZYeXh5MnVBNzJCN1BwYWJnYnJSZ3RhRTBOVnpnVEtWMDUwaVVUeEViQmxTZUIyV0h1YWFGMXNJT1dWU19kdnREMEdTUldSWWRHd2hmdkhVbzRiUzAxTmo0elZmQjhWVEJ6VlJPSW1oS3ZPWmR3eTJpMFRnWjd5V2hXU1lVYW5qSlJsczF6UkhyRmVVX0VvVk1KTGRBUy1UdGZpTlEyQkxGNWdOYXlXcXRRcnEyZm0?oc=5","date":"2025-03-27","type":"pipeline","source":"Stock Titan","summary":"Game-Changing Cancer Detection: New Test Successfully Identifies 5 Common Cancers - Stock Titan","headline":"Game-Changing Cancer Detection: New Test Successfully Identifies 5 Common Cancers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPYkYtNGkzZU5JRmlEM3cxQ1U5Zlk2NzFlNDBLOXVCRWE3dVVDZFpOcFBUWFdfdUZMR2FpaDVISG5vdndHZjBWSE05OEYza1luODRYNlFUZ0IxdjU3djJCVnhFMXJfQ3JlRG04Q0drOW9mOGF3NThpQmpxbm9OZ1hlZEdnSVhnekRNZkRXYVRJQzJVMENDUlB6WUdoVHFzbU5Xb0Q2eGM2Z0d1Vmpmdi1DSF9tSDJjQm1SVHA0bGZB?oc=5","date":"2025-01-30","type":"trial","source":"Stock Titan","summary":"Game-Changing Sepsis Detection: 971-Patient Study Validates Revolutionary Blood Test - Stock Titan","headline":"Game-Changing Sepsis Detection: 971-Patient Study Validates Revolutionary Blood Test","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Exact Sciences","Invitae","Foundation Medicine"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":1727384,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":1727384,"period":"2025-12-31"},{"value":1233511,"period":"2024-12-31"},{"value":775302,"period":"2023-12-31"},{"value":306392,"period":"2022-12-31"},{"value":90035,"period":"2021-12-31"},{"value":13433,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":10081299,"rdSpendHistory":[{"period":"2025-12-31","value":10081299},{"period":"2024-12-31","value":14406486},{"period":"2023-12-31","value":19551523},{"period":"2022-12-31","value":15332989}],"sgaSpend":13201611,"operatingIncome":-21222056,"operatingIncomeHistory":[{"period":"2025-12-31","value":-21222056},{"period":"2024-12-31","value":-26921602},{"period":"2023-12-31","value":-35773244},{"period":"2022-12-31","value":-30550647}],"netIncome":-23357027,"netIncomeHistory":[{"period":"2025-12-31","value":-23357027},{"period":"2024-12-31","value":-26967836},{"period":"2023-12-31","value":-35319078},{"period":"2022-12-31","value":-30268793}],"eps":-6.2,"epsHistory":[{"period":"2024-12-31","value":-6.2},{"period":"2023-12-31","value":-10},{"period":"2022-12-31","value":-11},{"period":"2021-12-31","value":-10.2}],"cash":1117028,"cashHistory":[{"period":"2025-12-31","value":1117028},{"period":"2024-12-31","value":3264429},{"period":"2023-12-31","value":20729983},{"period":"2022-12-31","value":10867050}],"totalAssets":6901227,"totalLiabilities":42494038,"totalDebt":11464730,"equity":-34246393,"operatingCashflow":-19683334,"operatingCashflowHistory":[{"period":"2025-12-31","value":-19683334},{"period":"2024-12-31","value":-25893624},{"period":"2023-12-31","value":-18062999},{"period":"2022-12-31","value":-15277742}],"capex":-89558,"capexHistory":[{"period":"2025-12-31","value":-89558},{"period":"2024-12-31","value":-573852},{"period":"2023-12-31","value":-1083749},{"period":"2022-12-31","value":-1570182}],"freeCashflow":-19772892,"dividendsPaid":null,"buybacks":0,"employees":75,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":2755919,"ebit":-5232262,"ebitda":-4951697,"period":"2025-12-31","revenue":447034,"epsBasic":null,"netIncome":-6270832,"rdExpense":2468071,"epsDiluted":null,"grossProfit":null,"operatingIncome":-4731280},{"sga":3396852,"ebit":-4536361,"ebitda":-4227334,"period":"2025-09-30","revenue":627277,"epsBasic":-1,"netIncome":-5378358,"rdExpense":2285907,"epsDiluted":-1,"grossProfit":null,"operatingIncome":-4868806},{"sga":3938217,"ebit":-5865409,"ebitda":-5546866,"period":"2025-06-30","revenue":406688,"epsBasic":-1.2,"netIncome":-6284078,"rdExpense":2720207,"epsDiluted":-1.2,"grossProfit":null,"operatingIncome":-6221816},{"sga":3110623,"ebit":-5379958,"ebitda":-5071692,"period":"2025-03-31","revenue":246385,"epsBasic":-1.2,"netIncome":-5423759,"rdExpense":2607444,"epsDiluted":-1.2,"grossProfit":null,"operatingIncome":-5400154},{"sga":3334023,"ebit":-5764736,"ebitda":-5412619,"period":"2024-12-31","revenue":191657,"epsBasic":null,"netIncome":-5793373,"rdExpense":2587380,"epsDiluted":null,"grossProfit":null,"operatingIncome":-5763350},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-1.4,"netIncome":null,"rdExpense":null,"epsDiluted":-1.4,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2.22,"previousClose":2.36,"fiftyTwoWeekHigh":18.8,"fiftyTwoWeekLow":2.01,"fiftyTwoWeekRange":"2.01 - 18.8","fiftyDayAverage":3.34,"twoHundredDayAverage":7.24,"beta":1.03,"enterpriseValue":27702070,"forwardPE":0.5,"priceToBook":-8.18,"priceToSales":10.42,"enterpriseToRevenue":16.04,"enterpriseToEbitda":-1.33,"pegRatio":0,"ebitda":-20754864,"ebitdaMargin":0,"freeCashflow":-8515099,"operatingCashflow":-19683334,"totalDebt":11464730,"debtToEquity":0,"currentRatio":0.17,"returnOnAssets":-166.7,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":4,"targetMeanPrice":29.21,"targetHighPrice":60,"targetLowPrice":16.83,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":13.2,"institutionHeldPercent":16.9,"sharesOutstanding":8087955,"floatShares":6880463,"sharesShort":269068,"shortRatio":1.27,"shortPercentOfFloat":3.3,"epsTrailing":-4.4,"epsForward":4.8,"revenuePerShare":0.32,"bookValue":-0.27,"officers":[{"age":54,"name":"Mr. Cameron  Reynolds MBA","title":"Founder, CEO, President & Director"},{"age":52,"name":"Dr. Gaetan  Michel Ph.D.","title":"Chief Operating Officer"},{"age":55,"name":"Mr. Terig  Hughes","title":"CFO & Treasurer"},{"age":69,"name":"Dr. Jacob Vincent Micallef MBA, Ph.D.","title":"Chief Scientific Officer"},{"age":54,"name":"Mr. Nicholas  Plummer","title":"Group General Counsel"},{"age":54,"name":"Ms. Louise Batchelor  Day","title":"Group Chief Marketing & Communications Officer"},{"age":44,"name":"Mr. Gael  Forterre M.B.A.","title":"Chief Commercial Officer"},{"age":null,"name":"Ms. Sharon  Ballesteros","title":"U.S. Head of Quality & Development Process"}],"industry":"Medical Devices","irWebsite":"","website":"https://volition.com","phone":"512 774 8930"}}